Clinical Trial Update: A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating pyridoxamine to reduce urine oxalate in people with nephrolithiasis or hyperoxaluria has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Nephrolithiasis

Drugs mentioned

• Pyridoxamine (pyridoxamine)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Kidney Stones | Phase 2 | Status: WITHDRAWN